Kamei K, Shiraki Y, Koga T, Sakai K
Department of Pharmacology, Fujigotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, Shizuoka, Japan.
J Pharm Pharmacol. 1989 Apr;41(4):279-80. doi: 10.1111/j.2042-7158.1989.tb06454.x.
The effect of a new orally active angiotensin converting enzyme (ACE) inhibitor, calcium (-)-N-[(S)-3-[(N-cyclohexylcarbonyl-D-alanyl)thio]-2-methylpropionyl+ ++]-L- prolinate (MC-838, altiopril calcium), on systemic blood pressure (SBP) and tissue ACE activity has been examined in conscious spontaneously hypertensive rats (SHRs). MC-838 (3 mg kg-1) given orally to SHRs elicited a long-lasting hypotension lasting over 24 h. With the development of the hypotension, MC-838 significantly reduced ACE activity in the lung, kidney and aorta, but not in the brain and heart. Suppression of plasma ACE and rise of plasma renin activity occurred only transiently at an earlier stage.
